Zynerba Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
17.62 M |
Public Float |
11.46 M |
Zynerba Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.27 |
Market Cap |
$325.4 M |
Shares Outstanding |
21.07 M |
Public Float |
14.68 M |
Address |
80 West Lancaster Avenue Devon Pennsylvania 19333 United States |
Employees | - |
Website | http://zynerba.com |
Updated | 07/08/2019 |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. |